Sylvie GrÉgoire
Chairman
Pharmaceuticals Industries
Corvidia Therapeutics
Switzerland
Biography
He has over 25 years of international experience in the biotech and pharmaceutical industries. Sylvie was President of Shire Human Genetic Therapies (HGT), a business unit of Shire plc that focuses on Rare Diseases. Under her leadership, the business unit grew from $300M to $1.5B. Prior to joining Shire HGT, Sylvie was Executive Chairwoman of IDM Pharma. She was previously CEO of GlycoFi, a privately held protein technology company, held executive positions at Biogen Inc., and worked at Merck & Co. in the US and abroad. Sylvie is also a non-executive member of the board of 3 public companies: Galenica, a Swiss pharmaceutical company, NovoNordisk a Danish pharmaceutical company and PerkinElmer an instrumentation and diagnostics company. She has a depth of experience in the management of commercial operations, manufacturing and regulatory affairs. Sylvie holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.
Research Interest
Pharmaceuticals Industries
